Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis
Gerardo Rosati(Ospedale San Carlo), Stefano Tamberi(Azienda Unità Sanitaria Locale Della Romagna), Fabrizio Artioli(Roche (Switzerland)), Monica Ronzoni, Francesca Galli(University of Modena and Reggio Emilia), Rodolfo Mattioli(Ospedali Riuniti Marche Nord), Francesca Bergamo(Istituto Oncologico Veneto), Giacomo Bregni(Institut Jules Bordet), Paolo Marchetti(Istituto Dermopatico dell'Immacolata), Maurizio Cantore, Eliana Rulli(Mario Negri Institute for Pharmacological Research), Domenico Corsi(Ospedale San Carlo), Anna Maria Bochicchio(Ospedale San Carlo), Lorenza Rimassa(Humanitas University), Maria Di Bartolomeo(Fondazione IRCCS Istituto Nazionale dei Tumori), Giovanni Gerardo Cardellino(Ospedale Santa Maria della Misericordia di Udine), Maria Giulia Zampino(Azienda Ospedaliera Universitaria Pisana), Roberto Labianca(Ospedale Papa Giovanni XXIII), Fabio Galli(Mario Negri Institute for Pharmacological Research), Maria Banzi(Azienda Ospedaliera S.Maria), Domenico Bilancia(Azienda Ospedaliera Ospedale San Carlo Borromeo)
Cited by 11
Related Papers
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k